SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose Significant 9.98% Stake in MacroGenics Inc.

Armistice Capital, LLC and Steven Boyd have reported a 9.98% beneficial ownership stake in MacroGenics Inc., holding 6,296,000 shares of common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd are the reporting persons for this Schedule 13G filing.
• The filing pertains to their beneficial ownership of Common Stock, par value $0.01 per share, of MACROGENICS INC.
• As of March 31, 2025, the reporting persons collectively beneficially own 6,296,000 shares of MacroGenics Inc. common stock.
• This ownership represents 9.98% of the total class of securities outstanding.
• The percentage of ownership is calculated based on 63,090,323 shares outstanding as of March 14, 2025, as reported in MacroGenics Inc.'s Form 10-K filed on March 20, 2025.
• Armistice Capital, LLC and Steven Boyd share both voting and dispositive power over all 6,296,000 beneficially owned shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive investment by a notable institutional investor, which can be viewed positively as a vote of confidence, without suggesting any immediate negative implications or control contests.

Positives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, have taken a substantial 9.98% stake in MacroGenics Inc., indicating a notable investment interest.
• The investment is stated to be for ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive, long-term investment perspective rather than an activist one.

Risks

• No specific company-related risks are detailed in this beneficial ownership filing, as its primary purpose is to disclose ownership.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Statement from Armistice Capital, LLC and Steven Boyd)

Industry Context

This filing is a routine disclosure of significant beneficial ownership and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector where MacroGenics Inc. operates.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be seen as a positive signal, potentially increasing stock liquidity and investor confidence.
• Company Management: Awareness of a significant passive investor, but no direct impact on operations or strategy is implied by a 13G filing.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership or the nature of their investment.

Key Dates

Keywords

MACROGENICS INC, MGEN, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake